Medicenna Receives Non-Dilutive Grant Payment

Wednesday, May 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO and HOUSTON, May 1, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$757,940 (approximately, CD$1.02M) from the Cancer Prevention and Research Institute of

Texas ("CPRIT"). The payment is part of a total non-dilutive grant of up to US$14.1 million which is repayable out of potential future revenues associated with commercial sale of products developed with the grant proceeds.

The funds received represent a partial reimbursement for eligible expenditures incurred by Medicenna related to the MDNA55 Phase 2b clinical trial for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer. 

About MedicennaMedicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers.  Medicenna's wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Supported by a non-dilutive grant of up to US$14.1M from CPRIT, Medicenna's lead IL4-EC, MDNA55 has completed enrolling patients in a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has been used in five clinical trials in 132 patients, including 112 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit www.medicenna.com.

Cision View original content:http://www.prnewswire.com/news-releases/medicenna-receives-non-dilutive-grant-payment-300841464.html

SOURCE Medicenna Therapeutics Corp.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store